A Phase 1b/2 Study to Evaluate the Efficacy and Safety of Pembrolizumab in Combination With Investigational Agents for the Treatment of Participants With PD-1/L1-refractory Extensive-Stage Small Cell Lung Cancer in Need of Second-Line

Grants and Contracts Details

StatusFinished
Effective start/end date11/16/21 → 9/13/24

Funding

  • Merck Sharp & Dohme Corporation: $34,710.00